Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.

Slaby O, Sachlova M, Bednarikova M, Fabian P, Svoboda M, Vytopilova S, Valik D, Vyzula R.

Cancer Biother Radiopharm. 2010 Apr;25(2):237-43. doi: 10.1089/cbr.2009.0708.

PMID:
20423238
2.

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.

Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C, Conte PF.

Ann Oncol. 2000 Sep;11(9):1127-30.

PMID:
11061606
3.

Distribution and functional significance of somatostatin receptors in malignant melanoma.

Lum SS, Fletcher WS, O'Dorisio MS, Nance RW, Pommier RF, Caprara M.

World J Surg. 2001 Apr;25(4):407-12.

PMID:
11344389
4.

Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.

Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR.

Eur J Endocrinol. 2008 Mar;158(3):295-303. doi: 10.1530/EJE-07-0562.

5.

Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.

Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M.

J Clin Endocrinol Metab. 2015 Nov;100(11):E1437-45. doi: 10.1210/jc.2015-2792. Epub 2015 Sep 8.

PMID:
26348352
6.

Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.

Taboada GF, Luque RM, Bastos W, Guimarães RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP, Kineman RD, Gadelha MR.

Eur J Endocrinol. 2007 Jan;156(1):65-74.

7.

Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.

Muscarella LA, D'Alessandro V, la Torre A, Copetti M, De Cata A, Parrella P, Sperandeo M, Pellegrini F, Frusciante V, Maiello E, Merla G, Fazio VM, Vendemiale G.

Cell Oncol (Dordr). 2011 Oct;34(5):435-41. doi: 10.1007/s13402-011-0025-9. Epub 2011 Apr 19.

PMID:
21503779
8.

Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment.

Casarini AP, Jallad RS, Pinto EM, Soares IC, Nonogaki S, Giannella-Neto D, Musolino NR, Alves VA, Bronstein MD.

Pituitary. 2009;12(4):297-303. doi: 10.1007/s11102-009-0175-1.

PMID:
19330452
9.

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR.

Endocr Relat Cancer. 2015 Feb;22(1):1-9. doi: 10.1530/ERC-14-0360. Epub 2014 Nov 6.

10.

Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.

Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A.

Oncotarget. 2016 Feb 2;7(5):5538-47. doi: 10.18632/oncotarget.6686.

11.

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.

Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y.

J Clin Invest. 1994 Mar;93(3):1321-5.

12.

Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.

Strosberg JR, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski PB, Van Cutsem E, Öberg K, Pavel ME.

Endocr Relat Cancer. 2015 Dec;22(6):933-40. doi: 10.1530/ERC-15-0314. Epub 2015 Sep 15.

13.

Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.

Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.

Endocr J. 2007 Jun;54(3):371-8. Epub 2007 Apr 10.

14.

Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.

Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A, Jensen RT.

Cancer. 2002 Jan 15;94(2):331-43.

15.
16.

High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience.

Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ.

Cancer Biother Radiopharm. 2009 Oct;24(5):527-33. doi: 10.1089/cbr.2009.0644.

PMID:
19877882
17.

Somatostatin receptor subtype gene expression in pituitary adenomas.

Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A.

J Clin Endocrinol Metab. 1995 Apr;80(4):1386-92.

PMID:
7714115
18.

Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.

Hofland LJ, van der Hoek J, Feelders R, van der Lely AJ, de Herder W, Lamberts SW.

J Endocrinol Invest. 2005;28(11 Suppl International):36-42. Review.

PMID:
16625843
19.

Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.

Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S.

Breast Cancer Res Treat. 2005 Jul;92(2):175-86.

PMID:
15986128
20.

Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.

Janson ET, Oberg K.

Cancer Chemother Biol Response Modif. 2003;21:535-46. Review. No abstract available.

PMID:
15338762

Supplemental Content

Support Center